Company Overview and News

3
Lithium Junior Miner News For The Month Of September 2018

2018-09-25 seekingalpha
Lithium spot prices in China fall slightly, and global contract prices rise - The price gap is now closed.
LIT CXO SAV LAXXF LIACF CYDVF PFFOF WML POR ABEPF SQM MLNLF KOD AVLNF KDR SYA STLHF WMLLF LNRDY ADV ABE NGZ LMMFF GXY LRS PLU MNIKF HNR AMLM AVL ALB DMNXF MALRY LACDF MIN LKE DDXFF MGXMF PLUUF DJIFF PSC EMH CRECF LAC PLS NNO LTMCF DJI PDDTF NTTHF NNOMF AVLIF CYP MALRF ORE AVZ AJM

4
Lithium Junior Miner News For The Month Of August 2018

2018-08-27 seekingalpha - 1
Lithium market news - China’s lithium price decline is not the full picture to an industry surging.
LIT CXO SAV LAXXF LIACF AGY PFFOF WML POR ABEPF SQM MLNLF AVLNF AIS.H KDR SYA STLHF WMLLF LNRDY ADV ABE NGZ LMMFF GXY LRS PLU MNIKF HNR AMLM AVL ALB DMNXF MALRY MIN ARYMF LKE DDXFF MGXMF PLUUF DJIFF PSC EMH CRECF ERPNF PLS GSC NNO LTMCF DJI PDDTF NTTHF NNOMF AVLIF MALRF ORE AVZ AJM

4
Lithium Junior Miner News For The Month Of July 2018

2018-07-26 seekingalpha - 1
Lithium spot and contract price news - China spot prices slightly down in July, global contract prices remain strong.
LIT CXO SAV LAXXF LIACF PFFOF WML POR ABEPF SQM MLNLF AVLNF AIS.H SYA STLHF WMLLF LNRDY ABE NGZ LMMFF GXY LRS PLU MNIKF HNR AMLM AVL ALB DMNXF MALRY MIN LKE DDXFF MGXMF PLUUF DJIFF PSC EMH CRECF ERPNF PLS GSC NNO LTMCF DJI PDDTF NTTHF NNOMF AVLIF BCLMF MALRF ORE AVZ AJM

51
Lithium Junior Miner News For The Month Of June 2018

2018-06-27 seekingalpha - 1
Lithium market news: Joe Lowry significantly raised his new lithium demand forecast to ~800K MT LCE in 2025. Indian State-owned firms mandated to acquire overseas lithium and cobalt.
NI LIT CXO SAV LAXXF LIACF CYDVF AGY PFFOF WML POR ABEPF SQM MLNLF AVLNF AIS.H KDR SYA STLHF WMLLF LNRDY HMGLF PEMIF ABE NGZ LMMFF GXY LRS MNIKF PLU HNR AMLM 9984 AVL ALB DMNXF MALRY EEYMF SFTBF MIN NMKEF ARYMF LKE DDXFF MGXMF PLUUF DJIFF NMX PSC EMH CRECF ERPNF SFTBY PLS NNO DJI PDDTF NTTHF NNOMF CYP MALRF ORE AVZ AJM

1
Neometals supports Hannans’ lithium gold and nickel exploration strategy

2018-06-13 proactiveinvestors.com.au
Neometals Ltd (ASX:NMT) is the major shareholder of Hannans Ltd (ASX:HNR) with a 36% holding and supports its development of lithium, nickel and gold assets in Western Australia.
HNR WNARF WSA NMT

45
Lithium Junior Miner News For The Month Of April 2018

2018-05-01 seekingalpha - 1
Lithium spot and contract price news - Spot prices slightly down, while 2018 contract prices are up.
LIT CXO SAV LAXXF LIACF PFFOF WML POR ABEPF SQM MLNLF AVLNF AIS.H SYA STLHF WMLLF LNRDY HMGLF PEMIF ABE NGZ LMMFF GXY LRS PLU MNIKF HNR AMLM 9984 AVL ALB DMNXF SFTBF NMKEF LKE MGXMF PLUUF DJIFF NMX PSC EMH CRECF ERPNF SFTBY PLS MNTCF DJI PDDTF NTTHF AVLIF ORE AVZ AJM

5
Neometals Offers 4 Great Opportunities For The Price Of 1

2018-04-09 seekingalpha
This article was first published on Trend Investing on March 9, 2018: therefore all data is as of that date.
RRSSF KDR HNR MALRY RDRUY MALRF MIN

48
Lithium Junior Miner News For The Month Of March 2018

2018-03-28 seekingalpha - 1
Lithium spot and contract price news - Lithium spot prices moved sideways, whilst 2018 global LCE contract prices are up about 20%.
LIT SAV LAXXF LIACF PFFOF WML POR ABEPF SQM MLNLF VLKAY AVLNF AIS.H KDR SYA STLHF WMLLF LNRDY HMGLF PEMIF ABE NGZ LMMFF GXY LRS PLU MNIKF HNR AMLM AVL ALB DMNXF NMKEF LKE MGXMF PLUUF DJIFF NMX PSC EMH CRECF ERPNF PLS MSB DJI SSDIY PDDTF NTTHF AVLIF ORE AVZ AJM

2
Neometals to acquire Mt Edwards Lithium Project

2018-03-15 proactiveinvestors.com.au
Neometals Ltd (ASX:NMT) is acquiring the Mt Edwards Lithium Project near Kalgoorlie in Western Australia for a cash consideration of $2.5 million and additional contingent payments.
KDR HNR NMT

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:HNR / HANNANS REWARD LIMITED on message board site Silicon Investor.

High North Resources Inc. (HNRI), nee CSRS High North Resources Inc. (HNRI), nee CSRS High North Resources Inc. (HNRI), nee CSRS